Management options, survivorship, and emerging treatment strategies for follicular and Hodgkin lymphomas

References

• Stedman's concise medical dictionary (28th revised edition). Baltimore, MD: Lippincott Williams and Wilkins, 2005.
   Google Scholar
• Friedberg JW. Treatment of follicular NHL: the old and the new. Semin Hematol 2008;45(3 Suppl. 2):S2–S6.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Outlook brighter for patients with follicular lymphoma. 2009B; Available from: http://www.cancer.org/docroot/NWS/content/NWS_1_1x_Outlook_Brighter_for_Patients_With_Follicular_Lymphoma.asp [Accessed 17 November 2009].
   Google Scholar
• Salles GA. Clinical features, prognosis and treatment of follicular lymphoma. Hematology Am Soc Hematol Educ Progr 2007;216–225.
   PubMedGoogle Scholar
• American Cancer Society. What are the key statistics about Hodgkin disease? 2009A; Available from: http://www.cancer.org/docroot/CRI/content/CRI_2_4_1x_What_Are_the_Key_Statistics_About_Hodgkin_Disease.asp [Accessed 17 November 2009].
   Google Scholar
• National Cancer Institute. SEER incidence – crude rates for white/black/other, 1973–2006. 2009; Available from: http://canques.seer.cancer.gov/cgi-bin/cq_submit?dir=seer2006&db=4&rpt=LINE&sel=1∧0∧79∧0∧∧∧&x=Age%20at%20diagnosis∧6,7,8,9,10,11,12,13,14,15,16,17,18,19,20&y=Race∧0,1,2∧Sex∧0,1,2&dec=1&template=null [Accessed 17 November 2009].
   Google Scholar
• Straus DJ, Portlock CS, Qin J, et al Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004;104:3483–3489.
   PubMed Web of Science ®Google Scholar
• Rueda Dominguez A, Marquez A, Guma J, et al Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. Ann Oncol 2004;15:1798–1804.
   PubMed Web of Science ®Google Scholar
• Klimm B, Schnell R, Diehl V, Engert A. Current treatment and immunotherapy of Hodgkin's lymphoma. Haematologica 2005;90:1680–1692.
   PubMed Web of Science ®Google Scholar
• Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993;20(5 Suppl. 5):75–88.
   PubMed Web of Science ®Google Scholar
• Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984;311:1471–1475.
   PubMed Web of Science ®Google Scholar
• Mounter PJ, Lennard AL. Management of non-Hodgkin's lymphomas. Postgrad Med J 1999;75:2–6.
   PubMed Web of Science ®Google Scholar
• Redman J, Cabanillas F, McLaughlin P, et al Fludarabine monophosphate (FAMP) treatment of low-grade lymphoma (LGL). Proc Am Soc Clin Oncol 1991;283:989.
   Google Scholar
• Solal-Céligny P, Brice P, Brousse N, et al Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma. A multicentre study by the ‘Groupe d'Etude des Lymphomes de l'Adulte’. J Clin Oncol 1996;14:514–519.
   PubMed Web of Science ®Google Scholar
• Kay AC, Saven A, Carrera CJ, et al 2-chlorodeoxyadenosine treatment of lowgrade lymphomas. J Clin Oncol 1992;10:371–377.
   PubMed Web of Science ®Google Scholar
• Saven A, Emanuele S, Kosty M, Koziol J, Ellison D, Piro L. 2-chlorodeoxyadenosine activity in patients with untreated indolent non-Hodgkin's lymphoma. Blood 1995;86:1710–1716.
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A, et al CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417–1423.
   PubMed Web of Science ®Google Scholar
• Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005;23:8447–8452.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, et al Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a fourdose treatment program. J Clin Oncol 1998;16:2825–2833.
   PubMed Web of Science ®Google Scholar
• DeNardo SJ, Kroger LA, DeNardo GL. A new era for radiolabeled antibodies in cancer? Curr Opin Immunol 1999;11:563–569.
   PubMed Web of Science ®Google Scholar
• Zelenetz A. Radioimmunotherapy for lymphoma. Curr Opin Oncol 1999;11:375–380.
   PubMedGoogle Scholar
• Witzig TE, White CA, Gordon LI, et al Prospective randomized controlled study of ZevalinTM (IDEC-Y2B8) radioimmunotherapy compared to rituximab immunotherapy for B-cell NHL: report of interim results. Blood 1999;94: (Abstract 631).
   PubMed Web of Science ®Google Scholar
• Matasar M, Zelenetz A. Overview of lymphoma diagnosis and management. Radiol Clin N Am 2008;46:175–198.
   PubMed Web of Science ®Google Scholar
• Toze CL, Barnett MJ, Connors JM, et al Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation. Br J Haematol 2004;127:311–321.
   PubMed Web of Science ®Google Scholar
• van Besien K, Loberiza FR Jr, Bajorunaite R, et al Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003;102:3521–3529.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Taylor MD, Cerhan JR, et al Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 2009;27:1202–1208.
   PubMed Web of Science ®Google Scholar
• Matasar MJ, Saxena R, Wong EK, Filippa DA, Zelenetz AD. Practice patterns in the diagnosis of follicular lymphoma (FL): report from the national lymphomacare study (NLCS). Blood 2007;110: (Abstract 2613).
   Web of Science ®Google Scholar
• Solal-Céligny P, Roy P, Colombat P, et al Follicular lymphoma international prognostic index. Blood 2004;104:1258–1265.
   PubMed Web of Science ®Google Scholar
• Nabhan C, Taylor MF, Hirata J, et al Racial disparities in disease presentation, treatment, and response rates for follicular lymphoma (FL) in the United States (US): report from the National LymphoCare Study (NLCS). Blood 2009;114: (Abstract 1381).
   Web of Science ®Google Scholar
• Ardeshna KM, Smith P, Norton A, et al British national lymphoma investigation. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003;362:516–522.
   PubMed Web of Science ®Google Scholar
• Schulz H, Bohlius JF, Trelle S, et al Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007;99:706–714.
   PubMed Web of Science ®Google Scholar
• Solal-Céligny P, Imrie K, Belch A, et al Mabthera (rituximab) plus CVP chemotherapy for first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma (NHL): confirmed efficacy with longer follow-up. Blood (ASH Annual Meeting Abstracts) 2005;106 (Suppl.): (Abstract 350).
   Google Scholar
• Hiddeman W, Forstpointer R, Kneba M, et al The addition of rituximab to combination chemotherapy with CHOP has a long lasting impact on subsequent treatment in remission in follicular lymhoma but not in mantle cell lymphoma: results of two prospective randomized studies of the German low grade lymphoma study group (GLSG). Blood (ASH Annual Meeting Abstracts) 2004;104 (Suppl.): (Abstract 161).
   Google Scholar
• van Oers MH, Klasa R, Marcus RE, et al Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295–3301.
   PubMed Web of Science ®Google Scholar
• Al-Tourah AJ, Gill KK, Hoskins PJ, et al The impact of initial treatment of advanced stage indolent lymphoma on the risk of transformation. J Clin Oncol (ASCO Annual Meeting Proceedings Part I) 2006;24 (Suppl.): (Abstract 7510).
   Google Scholar
• Montoto S, Davies AJ, Matthews J, et al Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 2007;25:2426–2433.
   PubMed Web of Science ®Google Scholar
• Dave SS, Wright G, Tan B, et al Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159–2169.
   PubMed Web of Science ®Google Scholar
• Farinha P, Masoudi H, Skinnider BF, et al Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005;106:2169–2174.
   PubMed Web of Science ®Google Scholar
• Carreras J, Lopez-Guillermo A, Fox BC, et al High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006;108:2957–2964.
   PubMed Web of Science ®Google Scholar
• Lee AM, Clear AJ, Calaminici M, et al Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 2006;24:5052–5059.
   PubMed Web of Science ®Google Scholar
• Alvaro T, Lejeune M, Salvadó MT, et al Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 2006;24:5350–5357.
   PubMed Web of Science ®Google Scholar
• Glas AM, Knoops L, Delahaye L, et al Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 2007;25:390–398.
   PubMed Web of Science ®Google Scholar
• de Jong D, Koster A, Hagenbeek A, et al Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica 2009;94:70–77.
   PubMed Web of Science ®Google Scholar
• Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van't Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003;21:3431–3439.
   PubMed Web of Science ®Google Scholar
• Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007;109:1878–1886.
   PubMed Web of Science ®Google Scholar
• Hjermstad MJ, Oldervoll L, Fosså SD, Holte H, Jacobsen AB, Loge JH. Quality of life in long-term Hodgkin's disease survivors with chronic fatigue. Eur J Cancer 2006;42:327–333.
   PubMed Web of Science ®Google Scholar
• Rueffer U, Breuer K, Josting A, et al Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment. Ann Oncol 2001;12:1307–1311.
   PubMed Web of Science ®Google Scholar
• Sieniawski M, Reineke T, Nogova L, et al Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood 2008;111:71–76.
   PubMed Web of Science ®Google Scholar
• Mattle V, Behringer K, Engert A, Wildt L. Female fertility after cytotoxic therapy – protection of ovarian function during chemotherapy of malignant and non-malignant diseases. Eur J Haematol Suppl 2005;66:77–82.
   PubMedGoogle Scholar
• Matasar MJ, McCallen LN, Riedel ER, Ford JS, Oeffinger KC, Straus DJ. Late mortality and morbidity of patients with Hodgkin lymphoma treated in adulthood. J Clin Oncol 2009;27 (Suppl.): (Abstract 8547).
   Google Scholar
• Ford JS, Schwartz J, McCallen LN, et al Psychosocial functioning in survivors of Hodgkin lymphoma (HL) treated during adulthood. J Clin Oncol 2008;26 (Suppl.): (Abstract 9592).
   Google Scholar
• Huang XJ, Wang Y, Liu DH, et al Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia – feasibility and safety study. J Clin Immunol 2008;28:390–397.
   PubMed Web of Science ®Google Scholar
• Bollard CM, Gottschalk S, Leen AM, et al Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 2007;110:2838–2845.
   PubMed Web of Science ®Google Scholar
• Heslop HE, Slobod KS, Pule MA, et al Long term outcome of EBV specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010;115:925–935.
   PubMed Web of Science ®Google Scholar
• Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol 2002;20:70–75.
   PubMed Web of Science ®Google Scholar
• Vera J, Savoldo B, Vigouroux S, et al T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 2006;108:3890–3897.
   PubMed Web of Science ®Google Scholar
• Pule MA, Savoldo B, Myers GD, et al Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008;14:1264–1270.
   PubMed Web of Science ®Google Scholar
• Bollard CM, Rössig C, Calonge MJ, et al Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 2002;99:3179–3187.
   PubMed Web of Science ®Google Scholar
• Foster AE, Dotti G, Lu A, et al Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother 2008;31:500–505.
   PubMed Web of Science ®Google Scholar
• Di Stasi A, De Angelis B, Rooney CM, et al T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 2009;113:6392–6402.
   PubMed Web of Science ®Google Scholar